Bayer Bids To Become Cell Therapy Manufacturing Leader
The German group has invested $250m into a facility at its campus in Berkeley, CA to produce cell therapies from its own portfolio and for other companies in the space who are looking to tackle the perennial issue of manufacturing.
You may also be interested in...
The private US/Canadian firm is taking a singular approach to T-cell therapy to tackle both solid and liquid tumors and hopes to have early data to back up its novel technology this year. An IPO could follow.
Plus deals involving Advanz/Dimerix, Boehringer Ingelheim/Zeiss Medical Technology, Roche/Ionis, Kriya/Everads and updates from the world of technology transfer.
The fortunes of the foundation that controls Novo Nordisk and backs a wide range of scientific, humanitarian and social causes are set to be transformed by the spectacular commercial success of the weight loss blockbuster Wegovy.